首页> 外文期刊>Medical dosimetry: official journal of the American Association of Medical Dosimetrists >A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy
【24h】

A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy

机译:通过剂量调制放射疗法对局部晚期外阴癌进行根治性治疗的剂量递增剂量学评估

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this planning study was to determine whether intensity-modulated radiation therapy (IMRT) reduces the radiation dose to organs at risk (OAR) when compared with 3D conventional radiation therapy (3D-CRT) in patients with vulvar cancer treated by irradiation. This study also investigated the use of sequential IMRT boost (seq-IMRT) and simultaneous integrated boost (SIB-IMRT) for dose escalation in the treatment of locally advanced vulvar cancer. Five vulvar cancer patients treated in the postoperative setting and 5 patients treated with definitive intent (def-group) were evaluated. For the postoperative group, 3D-CRT and IMRT plans to a total dose (TD) of 45 Gy were generated. For the def-group, 4 plans were generated: a 3D-CRT and an IMRT plan to a TD of 56.4 Gy, a SIB-IMRT plan to a TD of 56 Gy, and a SIB-IMRT with dose escalation (SIB-IMRT-esc): TD of 67.2 Gy. Mean dose and dose-volume histograms were compared using Student's t-test. IMRT significantly (all p 0.05) reduced the D mean, V30, and V40 for all OAR in the adjuvant setting. The V45 was also significantly reduced for all OAR except the bladder. For patients treated in the def-group, all IMRT techniques significantly reduced the D mean, V40, and V45 for all OAR. The mean femur doses with SIB-IMRT and SIB-IMRT-esc were 47% and 49% lower compared with 3D-CRT. SIB-IMRT-esc reduced the doses to the OAR compared with seq-3D-CRT but increased the D max. for the small bowel, rectum, and bladder. IMRT reduces the dose to the OAR compared with 3D-CRT in patients with vulvar cancer receiving irradiation to a volume covering the vulvar region and nodal areas without compromising the dosimetric coverage of the target volume. IMRT for vulvar cancer is feasible and an attractive option for dose escalation studies.
机译:这项计划研究的目的是确定与通过放射治疗的外阴癌患者的3D常规放射疗法(3D-CRT)相比,调强放射疗法(IMRT)是否降低了对处于危险中的器官(OAR)的放射剂量。这项研究还研究了连续IMRT增强疗法(seq-IMRT)和同步综合增强疗法(SIB-IMRT)在局部晚期外阴癌治疗中剂量递增的用途。评估了5例在术后环境中接受治疗的外阴癌患者和5例接受了明确意图治疗的患者(def组)。对于术后组,生成了总剂量(TD)为45 Gy的3D-CRT和IMRT计划。对于def-group,生成了4个计划:3D-CRT和TD达到56.4 Gy的IMRT计划,SIB-IMRT达到TD 56 Gy的SIM-IMRT计划以及剂量递增的SIB-IMRT(SIB-IMRT) -esc):TD为67.2 Gy。使用学生t检验比较平均剂量和剂量-体积直方图。 IMRT显着(所有p <0.05)降低了佐剂中所有OAR的D均值,V30和V40。除膀胱外,所有OAR的V45值也显着降低。对于在def组中治疗的患者,所有IMRT技术均显着降低了所有OAR的D均值,V40和V45。与3D-CRT相比,SIB-IMRT和SIB-IMRT-esc的平均股骨剂量分别降低47%和49%。与seq-3D-CRT相比,SIB-IMRT-esc减少了OAR的剂量,但增加了D max。用于小肠,直肠和膀胱。与3D-CRT相比,IMRT在接受辐射至覆盖外阴区域和淋巴结区域的体积的外阴癌患者中,与3D-CRT相比,降低了OAR剂量,而不会影响目标体积的剂量学覆盖范围。 IMRT治疗外阴癌是可行的,并且是剂量递增研究的有吸引力的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号